CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
Budesonidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06268301
NCT06268301Phase 1Completed

A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Budesonide Oral Suspension in Healthy Adult Participants

Takeda·interventional·Posted Feb 20, 2024·Updated Dec 2, 2024

In Brief

A Phase 1 clinical trial evaluating Budesonide for Healthy Volunteers. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The main aim of this study is to check what the body of a healthy adult who either fasted or had eaten does to TAK-721 and how TAK-721 is distributed in and removed from the body. Other aims are to learn how safe the treatment with TAK-721 is and how suitable the TAK-721 is for healthy adults who either fasted or had eaten. All participants will receive TAK-721 but half will be assigned by chance to the participant group who are fasting first then getting the high-fat/high-calorie meal later or the group who gets meal first and fasts later. The group assignment will be switched once during the course of the study so that all participants will receive TAK-721 in both a fasted or fed condition.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202420252026
First PostedFeb 20, 2024
Enrollment StartFeb 6, 2023
Primary CompletionFeb 17, 2023
Study CompletionFeb 20, 2023
TodayJul 2, 2026
Enrollment to primary: 11 daysPosted 2.4 years ago

Interventions

Budesonidedrug

Budesonide oral suspension